Publications library Commentary or editorial
JWC · 2023
Serena, T. (sole author)
Journal of Wound Care, Vol 32, No 10, p685 (Oct 2023)
In this commentary, Dr. Thomas Serena responds to Medicare Administrative Contractor coverage decisions that removed coverage for more than 70 cellular, acellular, and matrix-like products (CAMPs) and limited the use of certain remaining products. He argues that the wound care community has not established consistent clinical evidence standards for these products and proposes that every CAMP seeking reimbursement should be supported by a randomized clinical trial enrolling more than 100 patients, followed by a real-world registry. The commentary introduces a proposed framework for evaluating CAMP evidence, with additional articles intended to detail the suggested requirements for clinical trials and registries.
Written by Dr. Thomas Serena, SerenaGroup's founder.
Plain-language summary by SerenaGroup. See the full text for complete methods and results.
No abstract is published for this item. Use the full text link for the complete document.
